Drug intelligence / Profile preview

ARR-002

Development stage: Phase 1
Lead developer: ArriVent BioPharma
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

ARR-002 is a next-generation antibody-drug conjugate (ADC) being developed as a novel therapeutic agent for the treatment of solid tumors. The drug is in preclinical development and represents part of ArriVent BioPharma's pipeline expansion into ADCs. It is being advanced through a partnership between Aarvik Therapeutics, which oversees preclinical studies, and ArriVent BioPharma, which will handle clinical development and commercialization. The specific target antigen or payload for this ADC has not been publicly disclosed as of June 2025[1][2][3].

Targets

MUC16 (Mucin-16)SLC34A2 (Sodium-dependent phosphate transporter type IIb)

Beyond the preview

Go deeper on ARR-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ARR-002.

Explore the full profile